Indication guide·Last updated June 15, 2025

Breast cancer

Reference guide to breast cancer treatment settings: hormone receptor, HER2, and triple-negative subtypes per public records.

This is a verified reference page — not a flagship Humanexa Review essay. Claims are sourced from structured evidence and updated on a reference schedule.

Indication overview

Breast cancer is heterogeneous by hormone receptor status, HER2 amplification, and molecular subtypes. Treatment spans surgery, radiation, endocrine therapy, chemotherapy, HER2-targeted agents, CDK4/6 inhibitors, and antibody-drug conjugates with approvals documented in FDA databases.

Market and competitive landscape

Competition varies by subtype: endocrine and CDK4/6 combinations in HR-positive disease, trastuzumab-based regimens and ADCs in HER2-positive disease, and immunotherapy plus chemotherapy in select triple-negative populations per FDA labels. Biomarker testing determines eligibility.

Key companies

Recent signals

FDA approval records document ADC label expansions in HER2-low and HER2-positive breast cancer.
ClinicalTrials.gov lists perioperative and metastatic trials across multiple sponsors.
SEC oncology filings reference breast cancer as a key indication for pipeline assets.

Sources

FDA Drugs@FDA databaseRegulatory communication · January 1, 2024
ClinicalTrials.govClinical trial registry · January 1, 2024
SEC EDGAR company filingsCompany filing · January 1, 2024

Indication overview

Market and competitive landscape

Key companies

Recent signals

Sources

Reference pages